MedTrace Logo

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

NCT01369745 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 294

Last updated 2014-05-15

Study results available
· View outcomes & findings →

Summary

Thus study will test an experimental drug called Z-102 (combination of prednisolone and dipyridamole) to treat patients with moderate to severe rheumatoid arthritis.

Conditions

Interventions

DRUG

Prednisolone

Prednisolone 2.7 mg daily

DRUG

dipyridamole

dipyridamole 360 mg daily

DRUG

Prednisone

Prednisone 5 mg daily

DRUG

Z102

Prednisolone 2.7 mg plus dipyridamole 360 mg daily

OTHER

placebo

Sponsors & Collaborators

  • Zalicus

    lead INDUSTRY

Principal Investigators

  • Margaret Lee, PhD · Zalicus, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2012-08-31
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01369745 on ClinicalTrials.gov